Daniel P. Petrylak, MD

Articles

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

April 10th 2024

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Dr Petrylak on Emerging Therapeutic Targets in Urothelial Cancer

April 4th 2024

Daniel Petrylak, MD, discusses emerging therapeutic targets showing early potential in metastatic urothelial cancer.

Dr Petrylak on Treatment With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

April 4th 2024

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Dr Petrylak on the Potential Use of Erdafitinib in Metastatic Urothelial Cancer

September 15th 2023

Daniel P. Petrylak, MD, discusses the potential uses for erdafitinib, highlighting key studies evaluating the use of the agent in patients with metastatic urothelial cancer.

Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

August 24th 2023

Daniel P. Petrylak, MD, discusses sequencing treatment selections in patients with FGFR2/3-altered metastatic urothelial cancer.

Dr. Petrylak on Results From the KEYNOTE-921 Trial of Pembrolizumab Plus Docetaxel in mCRPC

March 3rd 2023

Daniel P. Petrylak, MD, discusses efficacy and safety data from the phase 3 KEYNOTE-921 trial of pembrolizumab and docetaxel in metastatic castrate-resistant prostate cancer.

Dr. Petrylak on Enzalutamide Plus Androgen Deprivation Therapy in mHSPC

September 11th 2022

Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

March 14th 2022

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Dr. Petrylak on the Utilization of Enfortumab Vedotin in MIBC

February 18th 2022

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on Future Research in Prostate Cancer

October 22nd 2020

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Dr. Petrylak on the Utility of Tissue Versus Liquid Biopsy in Prostate Cancer

October 7th 2020

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Petrylak on the Role of PSA Screening in Prostate Cancer

September 28th 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

May 1st 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Dr. Petrylak on Available Treatment Options in Metastatic Bladder Cancer

March 13th 2020

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

June 4th 2019

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

June 9th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.